Total
0
Shares
Creso Pharma (ASX:CPH) - Chairman, Adam Blumenthal - The Market Herald
Chairman, Adam Blumenthal
Source: EverBlu Capital
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma's (CPH) target acquisition company Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin
  • Halucenex's inventory now totals 22.3 grams, making it one of the largest holders of GMP-grade synthetic psilocybin in Canada
  • Psilocybin is a hallucinogenic substance people ingest from certain types of mushrooms that grow throughout Europe, South America, Mexico and the U.S.
  • This additional supply allows Creso Pharma and Halucenex to increase the number of participants in its proposed clinical trials
  • Furthermore, Creso Pharma will explore the potential to combine synthetic psilocybin with existing products to create new offerings
  • Shares in Creso Pharma are steady on the market this morning and are trading at 18 cents

Creso Pharma's (CPH) target acquisition company Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin.

Halucenex's inventory now totals 22.3 grams, making it one of the largest holders of GMP-grade synthetic psilocybin in Canada.

Psilocybin is a hallucinogenic substance people ingest from certain types of mushrooms that grow throughout Europe, South America, Mexico and the U.S.

This additional supply allows Creso Pharma and Halucenex to increase the number of participants in its proposed clinical trials which are scheduled to begin in Q3 2021.

Furthermore, Creso Pharma will explore the potential to combine synthetic psilocybin with existing products to create new offerings.

"Halucenex is now one of the largest holders of single batch GMP grade synthetic psilocybin in Canada. This is a major development and opens a number of doors for Halucenex in medium and long term," Non-Executive Chairman Adam Blumenthal said.

"Once it secures its licence from Health Canada, Halucenex will have the capacity to progress a number of research and development initiatives, which have the potential to unlock new drug delivery methods and combinations," he added.

Shares in Creso Pharma are steady on the market this morning and are trading at 18 cents at 10:33 am AEST.

CPH by the numbers
More From The Market Herald
Adherium (ASX:ADR) - CEO, Rick Legleiter - The Market Herald

" Adherium (ASX:ADR) nabs supply contract for AstraZeneca study in US

Adherium (ADR) has been awarded a supply contract for an upcoming clinical study by AstraZeneca in the United States.
Dimerix (ASX:DXB) - MD and CEO, Dr Nina Webster - The Market Herald

" Dimerix’s (ASX:DXB) DMX-200 closer to COVID-19 study in India

The Indian regulatory agency has recommended that Dimerix’s (DXB) DMX-200 clinical study in COVID-19 patients be approved.
Antisense Therapeutics (ASX:ANP) - MD and CEO - The Market Herald

" Antisense Therapeutics (ASX:ANP) presents new data, files Australian patent

Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia.
Sigman (ASX:SIG) - CEO and Managing Director, Vikesh Ramsunder - The Market Herald

" Sigma Healthcare (ASX:SIG) appoints new CEO

Sigma Healthcare (SIG) has appointed a new Managing Director and CEO to lead the company.